| CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1) (NCT02824874) | Chong Kun Dang Pharmaceutical | 2016-04-01 |
| Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) (NCT02705859) | Cancer Trials Ireland | 2016-04-01 |
| Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection (NCT02648009) | Sunnybrook Health Sciences Centre | 2016-04-01 |
| A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects (NCT02753218) | LEO Pharma | 2016-04-01 |
| Mixture Nitrous Oxide - Oxygen 50-50% in Transrectal Prostate Biopsy Guided by Ultrasound (NCT02899182) | Universidade Federal Fluminense | 2016-04-01 |
| Aquamin and Prevention of Colon Cancer (NCT02647671) | James Varani | 2016-04-01 |
| A Trial of Doxycycline in Renal Disease (NCT02753426) | University of California, San Francisco | 2016-04-01 |
| Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors (NCT02740933) | Massachusetts General Hospital | 2016-04-01 |
| Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML (NCT02750995) | Daniel El Fassi | 2016-04-01 |
| Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis (NCT02704338) | Nanjing Medical University | 2016-04-01 |
| Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) (NCT02781480) | MeiraGTx UK II Ltd | 2016-04-01 |
| Pharmacokinetic Drug-Drug Interaction Study of Rucaparib (NCT02740712) | pharmaand GmbH | 2016-04-01 |
| Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas (NCT02822066) | First Affiliated Hospital of Zhejiang University | 2016-04-01 |
| A Treatment Study of Mucopolysaccharidosis Type IIIB (NCT02754076) | Allievex Corporation | 2016-04-01 |
| Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic (NCT02726711) | Vanderbilt University | 2016-04-01 |
| Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects (NCT02828397) | Regeneron Pharmaceuticals | 2016-04-01 |
| Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums (NCT03012763) | University Medicine Greifswald | 2016-04-01 |
| Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients (NCT03158012) | University of California, San Diego | 2016-04-01 |
| Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma (NCT02719379) | Rohit Divekar | 2016-04-01 |
| Drug Interaction Study of MGL-3196 With Atorvastatin (NCT02749578) | Madrigal Pharmaceuticals, Inc. | 2016-04-01 |
| Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma (NCT02696356) | BrightPath Biotherapeutics | 2016-04-01 |
| CKD-841 Pharmacokinetic/Pharmacodynamic Study (NCT03233932) | Chong Kun Dang Pharmaceutical | 2016-04-01 |
| Prophylactic Application of Donor-derived TCM After Allogeneic HSCT (NCT02758223) | Wuerzburg University Hospital | 2016-04-01 |
| Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants (NCT02731092) | University of Virginia | 2016-04-01 |
| Glutaminergic Transmission in Autism : Molecular Imaging Exploration (NCT02719951) | University Hospital, Tours | 2016-04-01 |
| CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia (NCT02443831) | University College, London | 2016-04-01 |
| Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (NCT02676869) | Immutep Australia Pty. Ltd. | 2016-04-01 |
| Decision Making Study in Young and Middle-Aged Adults: Part II (NCT03512171) | Vanderbilt University | 2016-03-31 |
| Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA (NCT02685332) | University of Texas Southwestern Medical Center | 2016-03-31 |
| DS-3201b in Participants With Lymphomas (NCT02732275) | Daiichi Sankyo Co., Ltd. | 2016-03-31 |
| A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers (NCT02711423) | Hoffmann-La Roche | 2016-03-31 |
| To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125 (NCT02673567) | Teva Branded Pharmaceutical Products R&D, Inc. | 2016-03-31 |
| A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors (NCT02705482) | MedImmune LLC | 2016-03-30 |
| Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy (NCT02603562) | aTyr Pharma, Inc. | 2016-03-30 |
| Safety Evaluation of Advantage Anti-Caries Varnish (NCT02645617) | Advantage Dental Services, LLC | 2016-03-30 |
| An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions (NCT02722239) | AstraZeneca | 2016-03-30 |
| Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) (NCT02684617) | Merck Sharp & Dohme LLC | 2016-03-29 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) (NCT02610062) | Astellas Pharma Global Development, Inc. | 2016-03-29 |
| Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults (NCT02685020) | Janssen Vaccines & Prevention B.V. | 2016-03-28 |
| Single Ascending Dose Study of AMG 570 in Healthy Subjects (NCT02618967) | Amgen | 2016-03-28 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia (NCT02720263) | Astellas Pharma Global Development, Inc. | 2016-03-28 |
| PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) (NCT02723877) | PIQUR Therapeutics AG | 2016-03-28 |
| Safety and Immunogenicity of Typhax, a Typhoid Vaccine (NCT03926455) | Matrivax Research and Development Corporation | 2016-03-28 |
| Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers (NCT02691702) | Biogen | 2016-03-28 |
| Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients (NCT02703298) | TaiRx, Inc. | 2016-03-25 |
| Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users (NCT02682225) | Janssen Research & Development, LLC | 2016-03-25 |
| GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers (NCT02714374) | Andrew Lowy | 2016-03-25 |
| Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma (NCT02583477) | AstraZeneca | 2016-03-25 |
| A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT02600897) | Hoffmann-La Roche | 2016-03-24 |
| A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors (NCT02699749) | Millennium Pharmaceuticals, Inc. | 2016-03-24 |
| ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer (NCT02514031) | University of Texas Southwestern Medical Center | 2016-03-24 |
| LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies (NCT02649673) | SCRI Development Innovations, LLC | 2016-03-23 |
| A Study of HMPL-689 in Healthy Volunteers (NCT02631642) | Hutchison Medipharma Limited | 2016-03-23 |
| A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male Volunteers (NCT03180242) | EirGenix, Inc. | 2016-03-22 |
| To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers (NCT02706925) | Boehringer Ingelheim | 2016-03-22 |
| Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects (NCT02710630) | Boehringer Ingelheim | 2016-03-22 |
| Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) (NCT02638090) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-22 |
| Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer (NCT03322020) | Asan Medical Center | 2016-03-21 |
| The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers (NCT02699372) | Hoffmann-La Roche | 2016-03-21 |
| Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae (NCT02583373) | Combioxin SA | 2016-03-21 |
| Topical Erythropoietin Hydrogel Formulation for Diabetic Foot Ulcers (NCT02361931) | Remedor Biomed Ltd | 2016-03-21 |
| Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration (NCT02716987) | Neurocrine Biosciences | 2016-03-21 |
| To Compare Efficacy of Low Dose Diclofenac (25mg) in Management of Postoperative Pain After Periodontal Flap Surgery (NCT03519152) | Tatyasaheb Kore Dental College | 2016-03-20 |
| A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects (NCT02688387) | GlaxoSmithKline | 2016-03-18 |
| Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis (NCT02630901) | Prothena Biosciences Limited | 2016-03-17 |
| A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (NCT02734004) | AstraZeneca | 2016-03-17 |
| A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects. (NCT02717858) | Novo Nordisk A/S | 2016-03-16 |
| Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers (NCT02696616) | Boehringer Ingelheim | 2016-03-16 |
| Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (NCT02706392) | Fred Hutchinson Cancer Center | 2016-03-16 |
| Cayenne Pepper Cataplasm - Safety Study (NCT03440125) | University of Primorska | 2016-03-15 |
| Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (NCT02568046) | Symphogen A/S | 2016-03-15 |
| Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing (NCT02805556) | ViiV Healthcare | 2016-03-15 |
| Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects (NCT03030430) | Bio-Thera Solutions | 2016-03-15 |
| A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years (NCT02696148) | Novo Nordisk A/S | 2016-03-14 |
| Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects (NCT02742766) | GlaxoSmithKline | 2016-03-14 |
| Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects (NCT02691325) | GlaxoSmithKline | 2016-03-14 |
| Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer (NCT02559024) | Providence Health & Services | 2016-03-14 |
| Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem inClinical Healthy Subjects (NCT03570970) | Sihuan Pharmaceutical Holdings Group Ltd. | 2016-03-14 |
| BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients (NCT04501341) | Indonesia University | 2016-03-14 |
| Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo (NCT02657408) | Boehringer Ingelheim | 2016-03-11 |
| MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors (NCT02699515) | Merck KGaA, Darmstadt, Germany | 2016-03-11 |
| A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers (NCT02688374) | GlaxoSmithKline | 2016-03-11 |
| Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) (NCT02603419) | Pfizer | 2016-03-10 |
| (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies (NCT02561988) | Blueprint Medicines Corporation | 2016-03-10 |
| Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients (NCT02500849) | City of Hope Medical Center | 2016-03-10 |
| A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy (NCT02670044) | Hoffmann-La Roche | 2016-03-09 |
| A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) (NCT02611323) | Hoffmann-La Roche | 2016-03-09 |
| Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) (NCT02192021) | Falo, Louis, MD | 2016-03-09 |
| The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years (NCT05126979) | St. Petersburg Research Institute of Vaccines and Sera | 2016-03-09 |
| An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. (NCT02657343) | Dana-Farber Cancer Institute | 2016-03-09 |
| Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (NCT02535312) | National Cancer Institute (NCI) | 2016-03-08 |
| Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer (NCT02575807) | Aduro Biotech, Inc. | 2016-03-08 |
| A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body (NCT02688088) | Eli Lilly and Company | 2016-03-08 |
| Oxytocin in Alcohol Use Disorder (NCT02711189) | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 2016-03-08 |
| Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women (NCT03060785) | Johns Hopkins University | 2016-03-08 |
| Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1 (NCT02706886) | Alnylam Pharmaceuticals | 2016-03-08 |
| Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (NCT02715284) | Tesaro, Inc. | 2016-03-07 |
| Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma (NCT02668393) | Boehringer Ingelheim | 2016-03-07 |
| Aerosol BCG Challenge Trial in Healthy UK Adults (NCT02709278) | University of Oxford | 2016-03-07 |
| A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (NCT02614066) | Kite, A Gilead Company | 2016-03-07 |